Get the Stockscreener App
8.6837
2.11%
0.1637
Engene Holdings Inc stock is traded at $8.6837, with a volume of 17,578.
It is up +2.11% in the last 24 hours and up +31.22% over the past month.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
See More
Previous Close:
$8.52
Open:
$8.69
24h Volume:
17,578
Relative Volume:
0.10
Market Cap:
$388.43M
Revenue:
-
Net Income/Loss:
$-103.21M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-26.70M
1W Performance:
-3.33%
1M Performance:
+31.22%
6M Performance:
-43.91%
1Y Performance:
+0.00%
1-Day Range:
$8.536
$8.88
1-Week Range:
$8.50
$9.25
52-Week Range:
$4.42
$18.40
Engene Holdings Inc Stock (ENGN) Company Profile
Name
Engene Holdings Inc
Sector
Industry
Phone
(514) 332-4888
Address
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Engene Holdings Inc Stock (ENGN) Latest News
enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference - StockTitan
Forbion growth opportunities fund acquires $4.99m in Engene Holdings shares By Investing.com - Investing.com South Africa
Forbion growth opportunities fund acquires $4.99m in Engene Holdings shares - Investing.com Australia
FY2024 EPS Estimates for enGene Boosted by Leerink Partnrs - MarketBeat
EnGene Announces $60 Million Private Placement Financing - Marketscreener.com
enGene Holdings Inc. (NASDAQ:ENGN) Sees Significant Growth in Short Interest - MarketBeat
enGene secures $60 million in private placement By Investing.com - Investing.com Canada
enGene Announces $60 Million Private Placement Financing - citybiz
Why enGene Holdings Stock Is Trading Higher - Benzinga
enGene secures $60 million in private placement - Investing.com
EnGene Holdings Shares Rise After $60M Private Placement - MarketWatch
enGene Holdings Secures $60 Million for Genetic Medicines - TipRanks
EnGene Holdings Inc. announced that it expects to receive CAD 60.148968 million in funding from a group of investors - Marketscreener.com
EnGene Holdings Inc. announced that it expects to receive $60.148968 million in funding from a group of investors - Marketscreener.com
enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer - citybiz
enGene Holdings Announces Key Executive Appointments - TipRanks
EnGene Holdings Inc. Announces Executive Changes - Marketscreener.com
enGene CTO Anthony Cheung transitions to CSO, Joan Connolly to succeed - TipRanks
enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Purchases $19,717.50 in Stock - MarketBeat
Forbion growth opportunities fund increases stake in Engene Holdings with $3 million purchase - Investing.com Australia
enGene Holdings Inc. (NASDAQ:ENGN) Receives $33.67 Average PT from Analysts - MarketBeat
Long Term Trading Analysis for (ENGN) - Stock Traders Daily
Short Interest in enGene Holdings Inc. (NASDAQ:ENGN) Rises By 130.0% - MarketBeat
(ENGN) Investment Report - Stock Traders Daily
Insider Buys Additional US$57k In enGene Holdings Stock - Yahoo Finance
This trade activity should not be overlooked: enGene Holdings Inc (ENGN) - SETE News
An Analysis of enGene Holdings Inc (ENGN)’s Potential Price Growth - Knox Daily
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - StockTitan
The Psychology of enGene Holdings Inc Inc. (ENGN) Price Performance: Understanding Market Sentiment - The InvestChronicle
enGene Holdings Inc. (NASDAQ:ENGN) CEO Ronald Harold Wilfred Cooper Buys 10,000 Shares - MarketBeat
engene CEO buys $57k in company shares - Investing.com
engene CEO buys $57k in company shares By Investing.com - Investing.com Canada
Perceptive Advisors LLC Trims Position in enGene Holdings Inc. (NASDAQ:ENGN) - MarketBeat
enGene Holdings Inc. (NASDAQ:ENGN) Sees Large Increase in Short Interest - MarketBeat
Engene shares hold as Oppenheimer stands by $30 target - Investing.com South Africa
Morgan Stanley maintains price target on Engene Holdings shares By Investing.com - Investing.com South Africa
Morgan Stanley maintains price target on Engene Holdings shares - Investing.com
EnGene Holdings Touches 52-Week Low After Drug Study Update - MarketWatch
The Future of enGene Holdings Inc: Analyzing ENGN - The InvestChronicle
enGene price target lowered to $17 from $26 at Leerink - TipRanks
SEC Form 424B3 filed by enGene Holdings Inc. - Quantisnow
enGene Holdings Excels in Bladder Cancer Treatment Trial - TipRanks
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort - Business Wire
(ENGN) Technical Data - Stock Traders Daily
enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Up 7,700.0% in September - Defense World
Engene stock poised for upside as key bladder cancer trial results nearOppenheimer - Investing.com India
enGene (NASDAQ:ENGN) Receives Outperform Rating from Oppenheimer - MarketBeat
Engene Holdings Inc Stock (ENGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Engene Holdings Inc Stock (ENGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Forbion Growth Opportunities F | 10% Owner |
Sep 30 '24 |
Buy |
6.34 |
341,332 |
2,163,362 |
2,400,791 |
| Forbion Growth Opportunities F | 10% Owner |
Sep 27 '24 |
Buy |
5.97 |
41,639 |
248,699 |
2,059,459 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 01 '24 |
Buy |
6.44 |
35,279 |
227,158 |
2,436,070 |
| Forbion Growth Opportunities F | 10% Owner |
Dec 29 '23 |
Buy |
9.06 |
10,020 |
90,771 |
2,017,820 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 07 '24 |
Buy |
6.55 |
11,844 |
77,531 |
2,469,833 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 02 '24 |
Buy |
6.37 |
10,153 |
64,697 |
2,446,223 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 04 '24 |
Buy |
6.54 |
5,997 |
39,242 |
2,457,989 |
| Forbion Growth Opportunities F | 10% Owner |
Dec 28 '23 |
Buy |
7.69 |
5,050 |
38,827 |
2,007,800 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 03 '24 |
Buy |
6.48 |
5,769 |
37,397 |
2,451,992 |
| Forbion Growth Opportunities F | 10% Owner |
Dec 27 '23 |
Buy |
7.17 |
2,750 |
19,711 |
2,002,750 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):